冠昊生物科技股份有限公司 第一章 总则 第一条 为进一步完善冠昊生物科技股份有限公司（以下简称"公司"）治 理机制，建立健全公司内部控制体系，切实提升信息披露质量，明确独立董事在 年报编制过程中的职责，充分发挥独立董事在年报披露方面的监督作用，根据《公 司法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 等法律法规、规范性文件及《公司章程》等有关规定，结合公司实际，制定本制 度。 第二条 独立董事年报工作制度包括汇报制度和沟通制度。独立董事应在公 司年报的编制和信息披露过程中，切实履行独立董事的责任和义务，勤勉尽责， 确保年报的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏。 第三条 独立董事行使职权时，公司有关人员应当积极配合，不得拒绝、阻 碍或隐瞒，不得干预其独立行使职权。 第二章 汇报制度 第四条 每个会计年度结束后，公司管理层应向每位独立董事全面汇报公司 本年度的生产经营情况和投融资活动等重大事项的进展情况，同时公司应安排每 位独立董事进行实地考察，上述事项应形成书面工作记录。 第五条 公司应当保证独立董事享有与其他董事同等的知情权。公司年度报 告中凡须经董事会决策的事项 ...

冠昊生物科技股份有限公司 信息披露管理办法 第一章 总则 第一条 为进一步规范冠昊生物科技股份有限公司(以下简称"公司")及其 他信息披露义务人的信息披露行为，加强公司信息披露事务管理，确保信息披露 内容的真实、准确、完整、及时、公平，以保护投资者利益及公司的长远利益， 根据《公司法》《证券法》《上市公司信息披露管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》等法律法规、规范性文件和《公司章程》等有关规定，结合 公司实际，制定本办法。 第二条 本办法所指信息披露义务人，包括： （一）公司董事会秘书和信息披露事务管理部门； （二）公司董事和高级管理人员； （三）公司董事会及其专门委员会； （四）公司各部门、各子公司及分公司的负责人； （五）公司控股股东、持股 5%以上的股东及其实际控制人； （六）其他负有信息披露职责的公司人员和部门。 第三条 本办法适用于公司各部门、各子公司及分公司。 第二章 信息披露的原则 第四条 信息披露基本原则： （一）信息披露义务人应当及时依法履行信息披露义务，披露的信息应当真 实、准确、完整，简明清晰、通俗易懂， ...

年度财务报告重大会计差错的更正和披露应严格遵守《公开发行证券的公司信息 披露编报规则第19号——财务信息的更正及相关披露》的规定执行，并聘请符合《证 券法》规定的会计师事务所对更正后的年度财务报告进行审计。 冠昊生物科技股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为进一步提高冠昊生物科技股份有限公司（以下简称"公司"）规范运作 水平，增强年报信息披露的真实性、准确性、完整性和及时性，加大对年报信息披露责 任人的问责力度，提高年报信息披露的质量和透明度，根据《证券法》《上市公司信息披 露管理办法》《上市公司治理准则》《公开发行证券的公司信息披露内容与格式准则第2 号——年度报告的内容与格式》《公开发行证券的公司信息披露编报规则第19号——财务 信息的更正及相关披露》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》等法律法规、规范性文件和《公司 章程》等有关规定，结合公司实际，制定本制度。 第二条 本制度所指责任追究制度是指年报信息披露工作中有关人员不履行或者不 正确履行职责、义务或其他个人原因导致年报信息发生重大差错，对公司造 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2025-053 冠昊生物科技股份有限公司 2025 年第三季度报告披露提示性公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 2025 年 10 月 28 日，冠昊生物科技股份有限公司(以下简称"公司")召开 了第六届董事会审计委员会第十四次会议和第六届董事会第十七次会议，审议通 过了公司《2025 年第三季度报告》。公司《2025 年第三季度报告》于 2025 年 10 月 29 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露。敬请投资者注意查阅。 特此公告。 冠昊生物科技股份有限公司董事会 2025 年 10 月 29 日 特别提示：本公司 2025 年第三季度报告于 2025 年 10 月 29 日在中国证监会 指定的创业板信息披露网站上披露，敬请投资者注意查阅。 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2025-054 冠昊生物科技股份有限公司 第六届董事会第十七次会议决议公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 1、冠昊生物科技股份有限公司(以下简称"公司")第六届董事会第十七次 会议，会议通知已于 2025 年 10 月 24 日以专人送达、邮件等方式送达全体董事。 2、本次会议于 2025 年 10 月 28 日下午 14:15 在公司会议室采取现场会议和 通讯会议相结合的方式召开。 3、本次会议应出席董事 5 名，实际出席会议董事 5 名。其中，董事孙峰女 士、独立董事邓超先生以通讯方式出席会议。 4、本次会议由公司董事长张永明先生召集并主持，公司部分高级管理人员 列席了会议。 5、本次会议的召集和召开符合《公司法》《公司章程》和《董事会议事规 则》的有关规定。 （一） 审议通过《关于公司<2025 年第三季度报告>的议案》 公司《2025 年第三季度报告》详见 2025 年 10 月 29 日刊登在中国证监会指 定的创业板信息披露网站巨潮资讯网（http:/ ...

Financial Performance - The company's revenue for Q3 2025 was ¥92,610,785.08, representing a 4.72% increase year-over-year[5] - Net profit attributable to shareholders decreased by 17.87% to ¥6,314,402.45 for the quarter[5] - The net profit after deducting non-recurring gains and losses surged by 358.61% to ¥6,016,683.90[5] - Total operating revenue for the third quarter reached ¥293,480,433.06, an increase of 5.8% compared to ¥278,135,520.40 in the previous year[19] - Net profit for the period was ¥20,429,167.53, slightly down from ¥20,658,923.30, indicating a decrease of 1.1%[20] - The company's gross profit margin was approximately 10.9%, compared to 10.2% in the previous year, showing an improvement[19] Assets and Liabilities - Total assets increased by 2.67% to ¥774,506,933.18 compared to the end of the previous year[5] - The total assets of the company increased to ¥774,506,933.18 from ¥754,399,831.41, representing a growth of 2.1%[17] - Current liabilities decreased to ¥152,297,698.75 from ¥177,990,961.77, a reduction of 14.5%[17] - Long-term borrowings rose significantly to ¥100,950,000.00 from ¥76,000,000.00, an increase of 32.5%[17] - The total equity attributable to shareholders increased to ¥572,121,327.51 from ¥542,358,105.24, reflecting a growth of 5.5%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥52,635,840.17, up 62.75%[5] - Net cash flow from operating activities increased to CNY 52,635,840.17, compared to CNY 32,342,033.71 in the previous period, reflecting a growth of 63.5%[23] - Cash inflow from operating activities totaled CNY 337,580,752.35, up from CNY 323,070,746.17, indicating a rise of 4.7%[22] - Cash outflow from investing activities was CNY 30,788,916.93, a decrease from CNY 60,133,403.09, showing a reduction of 48.8%[23] - Net cash flow from financing activities decreased to CNY 15,179,779.24 from CNY 35,785,043.84, a decline of 57.6%[23] - The ending balance of cash and cash equivalents increased to CNY 141,434,634.79 from CNY 104,349,485.07, reflecting a growth of 35.5%[23] - The company reported a net increase in cash and cash equivalents of CNY 36,950,834.68, compared to CNY 8,241,079.60 in the previous period[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,315[10] - The largest shareholder, Beijing Century Tianfu Venture Capital Center, holds 13.58% of shares, totaling 36,016,266 shares[10] - The second largest shareholder, Beijing Tianyou Ruiyuan Medical Technology Co., Ltd., holds 6.44% of shares, totaling 17,084,822 shares[10] - The third largest shareholder, Tibet Jingan Enterprise Management Consulting Co., Ltd., holds 3.77% of shares, totaling 10,000,000 shares[10] - Guangdong Zhiguang Biotechnology Co., Ltd. holds 2.76% of shares, totaling 7,310,000 shares, which are pledged[10] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[11] Expenses and Financial Metrics - Financial expenses surged by 319.33% to ¥2,714,845.66 due to interest expenses from project-specific loans[8] - Other income decreased by 80.64% to ¥1,723,707.23, primarily due to reduced government subsidies[8] - Research and development expenses totaled ¥26,237,061.42, a decrease of 3.1% from ¥28,093,493.13 in the prior year[20] - The basic earnings per share for Q3 2025 was ¥0.0238, a decrease of 4.80%[5] - The weighted average return on equity was 1.13%, down 0.31% from the previous year[5] Other Information - The company reported a significant increase in prepayments by 265.73% to ¥7,589,380.81, attributed to increased procurement[8] - The company has a bank loan application of RMB 10 million (¥10,000,000) with China Industrial and Commercial Bank, guaranteed by its wholly-owned subsidiaries[12] - The company did not undergo an audit for the third quarter financial report[25] - The company plans to implement new accounting standards starting from 2025[24]

Core Viewpoint - Guanhao Biological (300238) reported that as of October 20, 2025, the total number of shareholders is 28,525 [1] Summary by Relevant Categories - **Company Information** - Guanhao Biological has a total of 28,525 shareholders as of the specified date [1]

Core Viewpoint - The Ministry of Industry and Information Technology is implementing the recognition and review of "Little Giant" enterprises specializing in niche markets, in line with President Xi Jinping's directive to promote more specialized and innovative small and medium-sized enterprises [1]. Summary by Sections Recognition and Review Process - The recognition and review process for the 2025 "Little Giant" enterprises has been completed, including initial reviews and recommendations from provincial departments and expert evaluations [1]. Regional Statistics - A total of 3,482 new "Little Giant" enterprises were recognized in the seventh batch, while 3,916 enterprises passed the review for 2025 [3]. - Jiangsu Province leads with 807 new enterprises, followed by Guangdong Province with 691, and Zhejiang Province with 398 [3]. Detailed Lists of Enterprises - The article includes detailed lists of recognized enterprises, particularly from Ningbo City, which features numerous companies in various sectors such as electronics, materials, and technology [4][5][6][7].

Market Overview - The medical device sector increased by 0.72% on October 15, with TuoJing Life leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Top Performers - TuoJing Life (300642) closed at 25.85, up 10.38% with a trading volume of 294,900 shares and a transaction value of 756 million [1] - JiMin Health (603222) closed at 10.97, up 10.03% with a trading volume of 353,400 shares [1] - MaiLanDe (688273) closed at 43.90, up 9.75% with a trading volume of 47,500 shares [1] - KeFu Medical (301087) closed at 43.10, up 7.86% with a trading volume of 72,700 shares [1] - Rejing Bio (688068) closed at 170.79, up 6.96% with a trading volume of 34,700 shares [1] Underperformers - JinHao Medical (920925) closed at 34.05, down 3.81% with a trading volume of 15,400 shares [2] - DaBo Medical (002901) closed at 55.52, down 2.94% with a trading volume of 29,400 shares [2] - HuaDa ZhiZao (688114) closed at 68.57, down 2.93% with a trading volume of 52,400 shares [2] Capital Flow - The medical device sector saw a net inflow of 500 million in main funds, while retail investors experienced a net outflow of 214 million [2][3] - Major stocks like SaiNuo Medical (688108) had a net inflow of 129 million from main funds, while JiMin Health (603222) saw a net outflow of 471 million from retail investors [3]

Core Insights - The company shows signs of short-term recovery with revenue and profit growth, but faces long-term stagnation in core business growth and structural challenges [1] - The core business, particularly the hard dura mater patch segment, is under pressure from multiple factors including price system disruptions due to centralized procurement policies and competition from domestic products [1][6] - The company has not successfully developed a second growth curve, with ongoing reductions in R&D investment and low efficiency in technology transfer [1][8] Financial Performance - In the first half of 2025, the company reported revenue of 201 million yuan, a slight increase of 5.89% year-on-year, and a net profit of 20.4 million yuan, with a growth rate of only 1.27% [2] - Over the past five years, revenue has declined from 437 million yuan in 2020 to 377 million yuan in 2024, a cumulative decrease of 13.7% [2] - The first half of 2025 revenue represents only 53.3% of the total revenue for 2024, indicating potential challenges in achieving a full-year revenue of 400 million yuan [2] Core Business Challenges - The hard dura mater patch, which is the company's main product, generated 74.44 million yuan in the first half of 2025, accounting for 50.6% of the medical device segment's revenue [4] - Revenue growth for the biological dura mater patch was only 1.35%, and it experienced a decline of 14.7% in 2024 [4][6] - The average revenue growth rate for the biological dura mater patch from 2022 to 2024 was only 1.2%, significantly lower than the double-digit growth seen from 2019 to 2021 [4] Competitive Pressures - Centralized procurement policies have led to a price drop of approximately 30% for the hard dura mater patch, which has not been offset by volume increases [6] - Domestic competitors are rapidly advancing in technology, further intensifying market competition [6][10] - The company has not introduced significant upgrades to its hard dura mater patch products in over a decade, leading to stagnation in growth [7] R&D and Innovation - R&D spending has decreased from 57.9 million yuan in 2022 to 42.31 million yuan in 2024, with the proportion of R&D expenses to revenue falling from 15.4% to 9.6% [8] - The company has maintained a stable number of R&D personnel but has not achieved any capitalized R&D projects, indicating a lack of progress in converting R&D into revenue [8] - The company is exploring advanced fields like artificial liver and CAR-T but lacks synergy with its core dura mater patch business [8] Dependency on Core Product - The company is overly reliant on the hard dura mater patch, with other products in the medical device segment unable to significantly contribute to revenue [9] - Other medical device products, such as the chest repair membrane, have shown declining revenues, and the pharmaceutical and cell technology segments have also underperformed [9][10] - The hard dura mater patch holds a market share of 30%, but faces significant pricing pressure from centralized procurement [10]